Cargando…
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, witho...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106673/ https://www.ncbi.nlm.nih.gov/pubmed/37077201 http://dx.doi.org/10.3389/fmolb.2023.1176309 |